Actuate Therapeutics (ACTU) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NewcelX (NCEL) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 83.3% versus a loss of 90.3%. NewcelX is the larger company by market cap ($18.0 million vs $16.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | NCEL |
|---|---|---|
| Share price | $0.679 | $3.11 |
| Market cap | $16.31M | $17.96M |
| 1-day change | -6.24% | +2.47% |
| YTD return | -88.91% | +63.68% |
| 1-year return | -90.31% | -83.32% |
| 5-year return | — | -99.68% |
| P/E ratio (TTM) | — | 5.98 |
| EPS (TTM) | $-0.87 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $19.07 |
| 52-week low | $0.604 | $1.83 |
| Distance from 52-week high | -92.00% | -83.69% |
| Analyst consensus | none | none |
| Avg. price target upside | +1620.18% | +639.55% |
| Average volume | 391.80K | 12.22K |
| Shares outstanding | 24.01M | 5.78M |
| Employees | 12 | 9 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Healthcare · Biotechnology · 12 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Healthcare · Biotechnology · 9 employees
ACTU vs NCEL FAQ
Which is bigger, Actuate Therapeutics or NewcelX?
NewcelX (NCEL) is larger, with a market capitalization of $17.96M compared with $16.31M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or NCEL?
NCEL returned -83.32% over the past 12 months, compared with -90.31% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.